Tom is a founder of Wintermute Biomedical and co-inventor of the patented carboxylate salt technology. He brings over 26 years of research experience to the team. Beyond his role at Wintermute Biomedical, Tom's background includes serving as staff scientist for Sinapis Pharma, Chief Scientific Officer for VirtualMind, and a founder of FYR Diagnostics. Throughout his career, he has led teams that successfully secured over $6 million in grants and $7.3 million in equity funding, driving significant scientific advancements.

Bob Goodman is an investor and joined the Wintermute board in November 2020. He has been a mathematics instructor and a practicing attorney concentrating in the fields of personal injury and medical-related litigation.

‍

Paul Field has over 30 years of business development experience across a range of therapeutic areas, and a deep network in the global biopharmaceutical industry. His current roles include corporate advisory positions at Imunexus, Alsonex, Marinova and the Global Antibiotic R&D Partnership (GARDP) headquartered in Geneva. Paul has served on a number of Boards, and he is a Fellow of the Australian Institute of Company Directors (FAICD).

Margaret is a highly regarded executive leader and influential strategy and policy analyst with experience in evidence-based policy development and advice to government. She has a reputation for high level innovative and strategic thinking and planning across the public and NFP sectors.

Alyce obtained her PhD from the La Trobe Institute for Molecular Science, La Trobe University. She specialises in cancer immunology, molecular and cell biology.

Alyce leads the ZosterEase™ shingles clinical trial program. Joining Wintermute in 2021, Alyce oversees the trials' research, protocol design, and clinical/regulatory strategy to advance evidence-based, patient-centred therapies to address current shingles treatment gaps.

Carolyn has a Pharmacology degree consolidated by 15 years in varied commercial roles within the pharmaceutical industry. She spent 10 years building a highly successful private mobility aids equipment business which was acquired in 2019 by a private equity investor. Carolyn brings a strength of operational and commercial expertise.

Prof Levin, MD, FIDSA, FPIDS studies the immune response to herpes virus infections and methods of treating and preventing such infections, including antiviral therapy and active immunization. He does basic research on the nature of latency of herpes viruses in human neurons. A vaccine to prevent shingles in elderly individuals has been developed and licensed through his clinical research, and further investigations of this vaccine are in progress.

He is a Fellow of both the Infectious Diseases Society of America and the Pediatric Infectious Disease Society.

Prof Tony Cunningham, AO, FAHMS, MD, FRACP, FRCPA, FRSN is a highly experienced viral immunologist, infectious diseases clinician and scientist, well known internationally for his research on the immunology of HIV and herpesviruses, his work on vaccine development and trialling, especially for shingles and herpes, and as an antiviral expert.

Prof Cunningham has been a longstanding global consultant to GSK, Seqirus, and Merck on vaccines in the ageing and for shingles and herpes and recently to Moderna and Novavax for COVID vaccines.

Dr Aaron Wong, MBBS (Hons) USYD, BPharm, FRACGP is a Sydney-based Primary Care Physician whose work spans several metropolitan practices. His clinical interests include preventative medicine, chronic disease management, infectious diseases, and herpes virus infections with a practical focus on diagnosis, treatment, and patient supporting primary care. He is a Principal Investigator and leads multiple clinical trials across these therapeutic areas. Dr. Wong is passionate about advancing innovative therapies and ensuring that trial design and execution remain closely aligned with the needs of patients and clinicians alike.